Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Facing Up To A Tough Market: Alkermes Execs Hope Vivitrol Alcoholism Med Catches On

This article was originally published in The Pink Sheet Daily

Executive Summary

Unmet need in alcoholism is high, but awareness of drug treatment is low.

You may also be interested in...



Lundbeck/Biotie Aim To Open Up Alcoholism Market By Trying To Reduce, Not Stop, Drinking

H. Lundbeck AS is planning to file for approval in Europe in the second half of 2011 for nalmefene – a drug touted as a novel and potentially revolutionary way of treating alcoholism – but currently is not planning to file in the U.S., presumably due to intellectual property issues.

Lundbeck/Biotie Aim To Open Up Alcoholism Market By Trying To Reduce, Not Stop, Drinking

H. Lundbeck AS is planning to file for approval in Europe in the second half of 2011 for nalmefene – a drug touted as a novel and potentially revolutionary way of treating alcoholism – but currently is not planning to file in the U.S., presumably due to intellectual property issues.

Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa

Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel